Intervention
Adebrelimab
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 33 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
33 shownLow-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung CancerNCT07583550 · 2026-07-20
RECRUITINGA Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerNCT07229729 · 2025-11-24
RECRUITINGAdjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World StudyNCT07640048 · 2025-05-04
RECRUITINGSecond-line Immunotherapy for ES-SCLCNCT06853678 · 2025-02-28
RECRUITINGMulticenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)NCT06610734 · 2024-12-23
RECRUITINGAdebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain MetastasisNCT06418594 · 2024-10-10
RECRUITINGStudy of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast CancerNCT06433609 · 2024-08-05
RECRUITINGA Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerNCT06483282 · 2024-06-21
RECRUITINGA Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLCNCT06424899 · 2024-05-19
RECRUITINGAdebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast CancerNCT06149130 · 2024-01-11
RECRUITINGA Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT07822542 · 2026-10-31
NOT_YET_RECRUITINGTrastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung CancerNCT07836543 · 2026-09-01
NOT_YET_RECRUITINGAdebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical StudyNCT07398560 · 2026-02-01
NOT_YET_RECRUITINGA Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid TumorsNCT07173244 · 2025-09-15
NOT_YET_RECRUITINGA Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and ChemotherapyNCT07069270 · 2025-09-01
NOT_YET_RECRUITINGStudy of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast CancerNCT07041437 · 2025-06-30
NOT_YET_RECRUITINGA Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung CancerNCT07031154 · 2025-06-30
NOT_YET_RECRUITINGAdebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLCNCT07035392 · 2025-06-20
NOT_YET_RECRUITINGA Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNCT06963502 · 2025-05-30
NOT_YET_RECRUITINGHypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction TherapyNCT06914050 · 2025-04-01
NOT_YET_RECRUITINGA Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung CancerNCT06786312 · 2025-01-25
NOT_YET_RECRUITINGMRNA Neoantigen Vaccine in Non-Small Cell Lung CancerNCT06735508 · 2025-01-01
NOT_YET_RECRUITINGStudy of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast CancerNCT06470672 · 2024-12-01
UNKNOWNA Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid TumorsNCT06594874 · 2024-10-31
NOT_YET_RECRUITINGAdebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICCNCT06648525 · 2024-10-01
NOT_YET_RECRUITINGNeoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer PatientsNCT06592625 · 2024-09-20
UNKNOWNTo Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast CancerNCT06470633 · 2024-08-01
NOT_YET_RECRUITINGAdebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene MutationsNCT06299371 · 2024-04-15
NOT_YET_RECRUITINGA Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung CancerNCT06267170 · 2024-02-25
UNKNOWNAdebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNCT06236997 · 2024-02-10
NOT_YET_RECRUITINGRadiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)NCT06251492 · 2024-01-30
UNKNOWNEfficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast CancerNCT06229067 · 2024-01-19
NOT_YET_RECRUITINGA Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLCNCT06177925 · 2023-12-10
UNKNOWNCommon conditions
Non-Small Cell Lung Cancer6Advanced Breast Cancer3Breast Cancer3Small Cell Lung Cancer3Adebrelimab2Advanced Solid Tumors2Intrahepatic Cholangiocarcinoma (Icc)2Non Small Cell Lung Cancer2NSCLC2Small Cell Lung Cancer Extensive Stage2Small Cell Lung Carcinoma2Adebrelimab (SHR-1316)1Apatinib1Bronchial Neoplasms1Carcinoma, Bronchogenic1Carcinoma, Non-Small-Cell Lung1Castration-resistant Prostate Cancer1Chemotherapy1Colorectal Cancer1Extensive Stage Small Cell Lung Cancer (ES-SCLC)1Gastrointestinal Cancers1HER2-negative Breast Cancer Brain Metastases1Hormone-receptor-positive Breast Cancer1HR+/HER2- Breast Cancer1Human Epidermal Growth Factor 2 Negative Carcinoma of Breast1
Leading sponsors
Fudan University
3
Jiangsu Hansoh Pharmaceutical Co., Ltd.
3
Fujian Cancer Hospital
2
Henan Cancer Hospital
2
Tianjin Medical University Cancer Institute and Hospital
2
Beijing 302 Hospital
1
Beijing GoBroad Hospital
1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
1
Guangdong Provincial People's Hospital
1
Harbin Medical University
1
Jiangmen Central Hospital
1
Jin Ying
1
Liaoning Cancer Hospital & Institute
1
Ming Chen
1
Nanfang Hospital, Southern Medical University
1
Trial status mix
NOT_YET_RECRUITING18
RECRUITING10
UNKNOWN5
Phase mix
PHASE225
PHASE12
EARLY_PHASE11
NA1
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.